Anixa Biosciences (NASDAQ:ANIX) Posts Quarterly Earnings Results, Meets Expectations

Posted by Brian Himes on Sep 9th, 2026

Anixa Biosciences (NASDAQ:ANIX – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08), FiscalAI reports.

Anixa Biosciences Trading Down 2.4%

Shares of NASDAQ:ANIX traded down $0.07 during midday trading on Wednesday, hitting $2.83. The stock had a trading volume of 474,293 shares, compared to its average volume of 192,695. The company has a market capitalization of $96.29 million, a PE ratio of -9.13 and a beta of 0.51. The stock has a 50 day moving average price of $3.36 and a two-hundred day moving average price of $2.99. Anixa Biosciences has a 1 year low of $2.32 and a 1 year high of $5.46.

Wall Street Analyst Weigh In

Several equities analysts have commented on ANIX shares. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Finally, Weiss Ratings cut shares of Anixa Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.50.

Get Our Latest Research Report on ANIX

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, CEO Amit Kumar acquired 21,000 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were purchased at an average price of $2.50 per share, with a total value of $52,500.00. Following the completion of the acquisition, the chief executive officer directly owned 630,812 shares of the company’s stock, valued at approximately $1,577,030. The trade was a 3.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders purchased 50,024 shares of company stock worth $148,971. Insiders own 26.40% of the company’s stock.

Institutional Trading of Anixa Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC purchased a new position in Anixa Biosciences in the second quarter valued at about $33,000. Cetera Investment Advisers purchased a new stake in shares of Anixa Biosciences during the 4th quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares in the last quarter. Benjamin Edwards Inc. acquired a new stake in shares of Anixa Biosciences in the 2nd quarter worth approximately $37,000. Finally, Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

(Get Free Report)

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.